TIPE2 and neoplasm: Considering that ICB therapy mainly contributes to restoring the killing function of CTLs against tumor cells in tumor tissues [1], and TIPE2 deletion in MDSCs can re-sensitize tumors to ferroptosis therapy (Figure 4), we wanted to examine whether TIPE2-deficient MDSCs combined with ferroptosis induction and ICB therapy could represent a therapeutic option for tumor treatment.